Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Essential Therapeutics (ETRX) formerly Microcide (MCDE

No earlier versions found for this Subject.

Return to Essential Therapeutics (ETRX) formerly Microcide (MCDE

Microcide is postioned well in a key biotech area--finding solutions to antibiotic resistant bacteria. This area has been overlooked in the last decade, with most the emphasis on viral/AIDS research. Now we have strains of bacteria which are resistant to all antibiotics, including the "silver bullet" Vancomycin.

MCDE has the management and techical ability to accomplish the task--it's better positioned than any other company as a pure play in this area of biotech.